{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:46:14Z","timestamp":1772131574685,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.clinthera.2023.03.012","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T07:22:35Z","timestamp":1679642555000},"page":"390-399.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey"],"prefix":"10.1016","volume":"45","author":[{"given":"Ebuwa","family":"Igho-Osagie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9434-9507","authenticated-orcid":false,"given":"Kaylen","family":"Brzozowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marissa Grifasi","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Puenpatom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.03.012_bib0001","unstructured":"Centers for Disease Control and Prevention. COVID data tracker. Published March 28, 2020. Accessed July 12, 2022. https:\/\/covid.cdc.gov\/covid-data-tracker"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0254258","article-title":"Variable effects of underlying diseases on the prognosis of patients with COVID-19","volume":"16","author":"Choi","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0003","first-page":"e35","article-title":"Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis","volume":"8","author":"Emami","year":"2020","journal-title":"Arch Acad Emerg Med"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0004","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) drugs. https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/coronavirus-covid-19-drugs."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0005","unstructured":"National Center for Health Statistics. FastStats: Therapeutic drug use. https:\/\/www.cdc.gov\/nchs\/fastats\/drug-use-therapeutic.htm."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0006","unstructured":"US Food and Drug Administration. Drug development and drug interactions | Table of substrates, inhibitors and inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0007","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0008","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2147\/NDT.S157708","article-title":"Drug-drug interactions involving antidepressants: focus on desvenlafaxine","volume":"14","author":"Low","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0009","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2013.48","article-title":"Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs","volume":"108","author":"van Leeuwen","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","article-title":"Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update","volume":"37","author":"Wedemeyer","year":"2014","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/medicina58020183","article-title":"The prevalence of potential drug-drug interactions in CKD: a retrospective observational study of Cerrahpasa nephrology unit","volume":"58","author":"Shahzadi","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0012","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/jac\/dkaa340","article-title":"Drug interactions: a review of the unseen danger of experimental COVID-19 therapies","volume":"75","author":"Hodge","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0013","doi-asserted-by":"crossref","first-page":"e00705","DOI":"10.1002\/prp2.705","article-title":"Drug-drug interactions with candidate medications used for COVID-19 treatment: an overview","volume":"9","author":"Rezaee","year":"2021","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0014","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.7970","article-title":"Identification of drug interaction adverse events in patients with COVID-19: a systematic review","volume":"5","author":"Conti","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0016","unstructured":"Office of the Commissioner, US Food and Drug Administration. Emergency use authorization. Published online March 2, 2022. Accessed March 6, 2022. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/mcm-legal-regulatory-and-policy-framework\/emergency-use-authorization."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0017","series-title":"Coronavirus (COVID-19) Update: FDA authorizes drug combination for treatment of COVID-19","year":"2022"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0018","unstructured":"US Food and Drug Administration. FDA fact sheet for healthcare providers: emergency use authorization for Lagevrio (molnupiravir) capsules. Accessed August 8, 2022. https:\/\/www.fda.gov\/media\/155054\/download."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0019","unstructured":"US Food and Drug Administration. FDA fact sheet for healthcare providers: Emergency use authorization for Paxlovid. Accessed March 7, 2022. https:\/\/www.fda.gov\/media\/155050\/download."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0020","series-title":"StatPearls [Internet]","article-title":"Ritonavir","author":"Talha","year":"2022"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0021","unstructured":"Centers for Disease Control and Prevention. HIV Nexus clinician resources: HIV treatment and results. https:\/\/www.cdc.gov\/hiv\/clinicians\/treatment\/treatment-clinicians.html."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0022","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2012","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0023","unstructured":"US Food and Drug Administration. Drug development and drug interactions | Table of substrates, inhibitors and inducers. Accessed August 8, 2022. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-1."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0024","series-title":"COVID-19 drug interactions","year":"2022"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0025","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/FTD.0b013e31815c16f5","article-title":"Clinically important drug interactions potentially involving mechanism-based inhibition of Cytochrome P450 3A4 and the role of therapeutic drug monitoring","volume":"29","author":"Zhou","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0026","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/M22-0281","article-title":"Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions","volume":"175","author":"Marzolini","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0027","series-title":"Cancer drug interactions","year":"2023"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0028","unstructured":"Centers for Disease Control and Prevention. NHANES about NHANES. Accessed September 15, 2022. https:\/\/www.cdc.gov\/nchs\/nhanes\/about_nhanes.htm."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0029","unstructured":"US Department of Health and Human Services. NHANES survey methods and analytic guidelines. Published 2021. Accessed December 24, 2021. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/analyticguidelines.aspx#estimation-and-weighting-procedures."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0030","unstructured":"Centers for Disease Control and Prevention. NHANES tutorials module 3: weighting. Accessed July 12, 2022. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/tutorials\/module3.aspx."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0031","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1042","article-title":"Prescription medication use among children and adolescents in the United States","volume":"142","author":"Qato","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0032","unstructured":"Lexicomp. https:\/\/www.wolterskluwer.com\/en\/solutions\/lexicomp"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0033","unstructured":"Centers for Disease Control and Prevention. COVID-19, people with certain medical conditions. Updated May 2, 2022. Accessed March 7, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html."},{"key":"10.1016\/j.clinthera.2023.03.012_bib0034","article-title":"U.S. population at increased risk of severe illness from COVID-19","volume":"6","author":"Ajufo","year":"2021","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0035","series-title":"Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications","year":"2022"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0036","series-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003\u20132012","author":"Gu","year":"2014"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0037","unstructured":"Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, [2015-2016] [https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?Cycle=2017-2020] [2017-March 2020] [https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?BeginYear=2015]"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0038","first-page":"1","article-title":"Burden and prevalence of risk factors for severe COVID-19 in the ageing European population - a SHARE-based analysis","author":"Ahrenfeldt","year":"2021","journal-title":"Z Gesundh Wiss"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0039","article-title":"Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases","volume":"16","author":"SK","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.clinthera.2023.03.012_bib0040","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.clinthera.2023.03.012_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003490","article-title":"Social determinants of mortality from COVID-19: a simulation study using NHANES","volume":"18","author":"Seligman","year":"2021","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.clinthera.2023.03.012_bib0042","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.cmi.2020.12.018","article-title":"Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis","volume":"27","author":"Langford","year":"2021","journal-title":"Clin Microbiol Infect"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823001091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T19:05:24Z","timestamp":1719342324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823001091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0149291823001091"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.012","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., Rahway, NJ, USA and The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}